glp-1 obesity drug news today september 15 2025 Oral Pill Delivers Injection-Like Weight Loss Results in Clinical Trials New Guidelines on GLP-1 Drugs

Predictors of survival in never-smokers with non-small cell lung cancer: a large-scale, two-phase genetic study

El K, Douros JD, Willard FS et al (2023) The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets

6.3 Pre-existing conditions L-C19 symptoms are more prevalent in individuals with underlying diseases, such as diabetes, obesity, cardiovascular or neuropsychiatric related disorders (167)

This scenario analysis done by Morgan Stanley on the potential impact is staggering if you consider the arguments laid out earlier about the reflexive nature of a successful weight loss drug and the eventual deflation in popular pharmaceuticals to be accurate